- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00666991
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, Phase 1, dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticle paclitaxel (Nanotax) in patients with refractory malignancies principally confined to the peritoneal cavity.
Nanotax will be administered via intraperitoneal infusion once every 28 days (equals one treatment cycle), continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced.
This study will treat one patient per predefined dose level until one patient experiences a dose limiting toxicity (DLT) or until one patient has a Grade 2 or higher non-hematological toxicity or a Grade 3 or higher hematological toxicity during the first cycle of treatment. At this time, two additional patients will be treated at this dose level. If these 2 additional patients do not experience a DLT, then the next cohort of three patients will be treated at the next highest dose level. If 2/3 or 3/3 patients experience a DLT then the next cohort of three patients is enrolled at the next lower dose level. If 1/3 of the patients experience a DLT, then the next cohort of three patients is enrolled at the same dose level. If 0/3 patients experience a DLT, then the next cohort of three patients is enrolled at the next highest dose level. If 2 (or more)/6 patients at a given level experience a DLT, then the maximum tolerated dose has been exceeded and another cohort of three patients is treated at the next lower dose level.
The protocol will not treat above the highest dose level of 275 mg/m2.
Adverse event data will be collected throughout the study. Peritoneal fluid and blood samples will be collected prior to Nanotax administration and up to 14 days following infusion for Cycle 1 and Cycle 2 only. Evaluation of tumor response using RECIST criteria will be conducted following each treatment cycle.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
Wichita, Kansas, United States, 67208
- Cancer Center of Kansas
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Peggy and Charles Stephenson Oklahoma Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be at least 18 years of age.
- Patients must have histologic or cytologic diagnosis of carcinoma predominantly confined to the peritoneal cavity.
- Patients must have failed all potentially curative therapy and have no other systemic treatment options available for extra-peritoneal disease. Patients with ovarian cancer that are platinum sensitive must have failed primary and at least one salvage regimen. Patients may undergo surgical debulking prior to entry into the trial.
- At least 28 days must have elapsed since completion of any other previous chemotherapy treatment received prior to registration in this study.
- Patients may have received prior abdominal surgery greater than 2 weeks prior to registration. Patients must have recovered from all effects of the surgical procedure.
- Patients must have a Zubrod Performance Status of 0 - 2.
- Patients must have a pretreatment granulocyte count greater than or equal to 1,500/microliter and platelet count greater than or equal to 100,000/microliter obtained within 14 days prior to registration.
- Patients must have adequate renal function as documented by a serum creatinine less than or equal to 1.5 times the institutional upper limit of normal obtained within 14 days prior to registration.
- Patients must have adequate hepatic function as documented by a bilirubin of less than or equal to 2 times the institutional upper limit of normal and an SGOT less than 5 times the institutional upper limit of normal obtained within 14 days prior to registration. Patients with hepatobiliary stents are eligible for this trial if the bilirubin meets the above parameter.
- There should be no plans for the patient to receive concomitant radiation therapy, hormonal therapy, or other chemotherapy for their tumor while on this protocol.
Exclusion Criteria:
- Patients with active inflammatory bowel disease or chronic diarrhea
- Patients with uncontrolled hypertension, unstable angina, symptomatic congestive heart failure, myocardial infarction within previous 6 months or serious uncontrolled cardiac arrhythmia
- Patients with active infection requiring systemic therapy
- Pregnant or nursing women
- Patients with Grade 2 or greater sensory neuropathy (by NCI Common Toxicity Criteria) at the time of study registration
- Patients taking concomitant medications demonstrated to inhibit or induce CYP3A4 or CYP2C8
- Patients with pre-existing conditions that prohibit the use of intravenous dexamethasone at the recommended dose
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nanotax, 50 mg/m2
Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity
|
This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients.
Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced.
Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Other Names:
|
Experimental: Nanotax, 82.5 mg/m2
Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 82.5 mg/m2 once every 28 days until progression or unacceptable toxicity
|
This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients.
Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced.
Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Other Names:
|
Experimental: Nanotax, 125 mg/m2
Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 125 mg/m2 once every 28 days until progression or unacceptable toxicity
|
This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients.
Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced.
Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Other Names:
|
Experimental: Nanotax, 175 mg/m2
Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 175 mg/m2 once every 28 days until progression or unacceptable toxicity
|
This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients.
Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced.
Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Other Names:
|
Experimental: Nanotax, 225 mg/m2
Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 225 mg/m2 once every 28 days until progression or unacceptable toxicity
|
This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients.
Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced.
Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Other Names:
|
Experimental: Nanotax 275 mg/m2
Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 275 mg/m2 once every 28 days until progression or unacceptable toxicity
|
This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients.
Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced.
Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine maximum tolerated dose and to assess qualitative and quantitative toxicities
Time Frame: Through last patient visit
|
Through last patient visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine preliminary anti-tumor activity using RECIST criteria
Time Frame: Through last patient visit
|
Through last patient visit
|
Determine pharmacokinetics of intraperitoneal administration
Time Frame: Up to 14 days following Cycles 1 and 2
|
Up to 14 days following Cycles 1 and 2
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gary Johnson, M.D., University of Kansas Medical Center
- Principal Investigator: Julia Chapman, M.D., University of Kansas Medical Center
- Principal Investigator: Thomas K Schulz, M.D., Cancer Center of Kansas
- Principal Investigator: Kathleen Moore, MD, Peggy and Charles Stephenson Oklahoma Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Peritoneal Diseases
- Digestive System Neoplasms
- Abdominal Neoplasms
- Peritoneal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- HSC#11140
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peritoneal Neoplasms
-
University of Michigan Rogel Cancer CenterCompletedOvarian, Fallopian Tube, and Primary Peritoneal CancerUnited States
-
AstraZenecaCompletedOvarian, Fallopian Tube, Peritoneal Cancer, P53 MutationUnited States, Canada, Netherlands
-
Association Francaise de ChirurgieCompletedCarcinomatosis, PeritonealFrance
-
M.D. Anderson Cancer CenterCompletedPeritoneal CancerUnited States
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerUnited States, Australia, France
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnOvarian, Fallopian Tube and Peritoneal CancerUnited States
-
Hasselt UniversityZiekenhuis Oost-LimburgUnknownColorectal Peritoneal CarcinomatosisBelgium
-
University of California, San DiegoCompleted
-
Hospices Civils de LyonUnknownColorectal Peritoneal CarcinomatosisFrance
-
Gustave Roussy, Cancer Campus, Grand ParisTerminatedPatients With Gastric Peritoneal CarcinomatosisFrance
Clinical Trials on nanoparticulate paclitaxel
-
NanOlogy, LLCUS Biotest, Inc.Active, not recruitingLung Cancer | Lung Cancer, Nonsmall Cell | Neoplasm of Lung | Lung Cancer, Small CellUnited States
-
NanOlogy, LLCUS Biotest, Inc.TerminatedUrogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer AdenocarcinomaUnited States
-
DFB Soria, LLCUS Biotest, Inc.WithdrawnCervical Intraepithelial Neoplasia
-
DFB Soria, LLCUS Biotest, Inc.Completed
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
NanOlogy, LLCUS Biotest, Inc.WithdrawnKidney Cancer | Renal Cell Carcinoma | Renal Cell Cancer | Adenocarcinoma of Kidney | Adenocarcinoma, Renal